Reuters logo
BRIEF-Helix Biopharma announces FDA approval to accelerate dose escalation for U.S. Phase I clinical study
September 27, 2017 / 9:17 PM / 3 months ago

BRIEF-Helix Biopharma announces FDA approval to accelerate dose escalation for U.S. Phase I clinical study

Sept 27 (Reuters) - Helix Biopharma Corp

* Helix Biopharma Corp. Announces fda approval to accelerate dose escalation for U.S. Phase i clinical study

* Helix Biopharma Corp- U.S. Food and drug administration has approved an amendment to their U.S. Phase I study, protocol ldos001

* Helix Biopharma - ‍study to implement accelerated dose design up to 6μg/kg followed by standard 3+3 design for final 2 dosing cohorts, 9 and 12 μg/kg​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below